Top Stories
MMI is the third company backed under the partners' €150 million co-investment initiative in less than a year.
In an international study, PANXEON was highly sensitive in detecting stage 1 and 2 pancreatic cancer and also spotted high-grade dysplasia.
The software gives hospitals a three-day view of emerging staffing, bed and patient-flow pressures, while updating expected discharge dates every hour.
Real-world testing found 27% of providers missed an AI-produced transcript before a visit and some virtual-care patients dropped out before seeing a clinician.
The company has submitted its 3D Intelligence algorithm to the FDA, offering users more flexibility based on their individual insulin needs.
Conference News
These findings support the potential of MammaTyper® LRP as a locally available low cost molecular pre-screen for identifying patients having an Oncotype DX® RS ≤25 who are at low recurrence risk.”— Ri...
DALLAS, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more...
SAN DIEGO--(BUSINESS WIRE)--ClearNote Health, a company dedicated to improving early detection and monitoring for some of the deadliest cancers, today announced it will present new data for its Avante...
New digital technologies, including Synchrony and SynX, will be featured at HRXStereotaxis CEO to join main-stage panel on Autonomous EP SystemsST. LOUIS, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Stereotaxi...
OAKVILLE, Ontario, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Provera Care Inc. today announced that Hello Pearl (hellopearl.app), its family coordination and connection platform, has been selected for Spring...
